The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Blatt, Katharina ^a   Herrmann, Harald ^a,b   Mirkina, Irina ^b   Hadzijusufovic, Emir ^a,c   Peter, Barbara ^a,c   Strommer, Sabine ^a   Hoermann, Gregor ^a   Mayerhofer, Matthias ^a   Hoetzenecker, Konrad ^a   Klepetko, Walter ^a   Ghanim, Viviane ^a   Marth, Katharina ^d   Füreder, Thorsten ^a   Wacheck, Volker ^a   Valenta, Rudolf ^d   Valent, Peter ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; CD203C ANTIGEN; CD63 ANTIGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E RECEPTOR; LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG; IMIDAZOLE DERIVATIVE; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; QUINOLINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BASOPHIL; CANCER CELL CULTURE; CANCER INHIBITION; CELL ACTIVATION; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HISTAMINE RELEASE; HUMAN; HUMAN CELL; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; MAST CELL; MAST CELL LEUKEMIA; MOUSE; NONHUMAN; PROTEIN TARGETING; UPREGULATION; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CELL PROLIFERATION; DOWN REGULATION; DRUG ANTAGONISM; DRUG SCREENING; EVALUATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; PHYSIOLOGY; TUMOR CELL LINE;

MAMMALIA; MUS;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BASOPHILS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; HUMANS; IMIDAZOLES; IMMUNOGLOBULIN E; MALE; MAST CELLS; MICE; MICE, NUDE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PHOSPHATIDYLINOSITOL 3-KINASES; QUINOLINES; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84856396314     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029925     Document Type: Article

References (51)

1. Valent P, Bettelheim P, (1992) Cell surface structures on human basophils and mast cells: biochemical and functional characterization. Adv Immunol 52: 333-423.
2. Falcone FH, Haas H, Gibbs BF, (2000) The human basophil: a new appreciation of its role in immune responses. Blood 96: 4028-4038.
3. Metcalfe DD, (2008) Mast cells and mastocytosis. Blood 112: 946-956.
4. Kinet JP, (1999) The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology. Annu Rev Immunol 17: 931-972.
5. Nadler MJ, Matthews SA, Turner H, Kinet JP, (2000) Signal transduction by the high-affinity immunoglobulin E receptor Fc epsilon RI: coupling form to function. Adv Immunol 76: 325-355.
6. Kawakami T, Galli SJ, (2002) Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol 2: 773-786.
7. Kepley CL, Youssef L, Andrews RP, Wilson BS, Oliver JM, (2000) Multiple defects in Fc epsilon RI signaling in Syk-deficient nonreleaser basophils and IL-3-induced recovery of Syk expression and secretion. J Immunol 165: 5913-5920.
8. Marone G, Spadaro G, Patella V, Genovese A, (1994) The clinical relevance of basophil releasability. J Allergy Clin Immunol 94: 1293-1303.
9. Greenhawt M, Akin C, (2007) Mastocytosis and allergy. Curr Opin Allergy Clin Immunol 7: 387-392.
10. Valenta R, Ferreira F, Focke-Tejkl M, Linhart B, Niederberger V, et al. (2010) From allergen genes to allergy vaccines. Annu Rev Immunol 28: 211-41.
11. Peavy RD, Metcalfe DD, (2008) Understanding the mechanisms of anaphylaxis. Curr Opin Allergy Clin Immunol 8: 310-315.
12. Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD, (2002) Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol 81: 677-690.
13. Valent P, Akin C, Sperr WR, Mayerhofer M, Födinger M, et al. (2005) Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 46: 35-48.
14. Valent P, Schernthaner GH, Sperr WR, Fritsch G, Agis H, et al. (2001) Variable expression of activation-linked surface antigens on human mast cells in health and disease. Immunol Rev 179: 74-81.
15. Valent P, Hauswirth AW, Natter S, Sperr WR, Bühring HJ, et al. (2004) Assays for measuring in vitro basophil activation induced by recombinant allergens. Methods 32: 265-270.
16. Bühring HJ, Streble A, Valent P, (2004) The basophil-specific ectoenzyme E-NPP3 (CD203c) as a marker for cell activation and allergy diagnosis. Int Arch Allergy Immunol 133: 317-329.
17. de Weck AL, Sanz ML, Gamboa PM, Aberer W, Bienvenu J, et al. (2008) Diagnostic tests based on human basophils: more potentials and perspectives than pitfalls. Int Arch Allergy Immunol 146: 177-189.
18. Siraganian RP, (2003) Mast cell signal transduction from the high-affinity IgE receptor. Curr Opin Immunol 15: 639-646.
19. Rivera J, Fierro NA, Olivera A, Suzuki R, (2008) New insights on mast cell activation via the high affinity receptor for IgE. Adv Immunol 98: 85-120.
20. Serve H, Yee NS, Stella G, Sepp-Lorenzino L, Tan JC, et al. (1995) Differential roles of PI3-kinase and Kit tyrosine 821 in Kit receptor-mediated proliferation, survival and cell adhesion in mast cells. EMBO J 14: 473-483.
21. Timokhina I, Kissel H, Stella G, Besmer P, (1998) Kit signaling through PI 3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation. EMBO J 17: 6250-6262.
22. Fukao T, Yamada T, Tanabe M, Terauchi J, Ota T, et al. (2002) Selective loss of gastrointestinal mast cells and impaired immunity in PI3K-deficient mice. Nat Immunol 3: 295-304.
23. Shivakrupa R, Bernstein A, Watring N, Linnekin D, (2003) Phosphatidylinositol 3′-kinase is required for growth of mast cells expressing the kit catalytic domain mutant. Cancer Res 63: 4412-4419.
24. Harir N, Boudot C, Friedbichler K, Sonneck K, Kondo R, et al. (2008) Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood 112: 2463-2473.
25. Tedeschi A, Lorini M, Galbiati S, Gibelli S, Miadonna A, (2000) Inhibition of basophil histamine release by tyrosine kinase and phosphatidylinositol 3-kinase inhibitors. Int J Immunopharmacol 22: 797-808.
26. Lusková P, Dráber P, (2004) Modulation of the Fcepsilon receptor I signaling by tyrosine kinase inhibitors: search for therapeutic targets of inflammatory and allergy diseases. Curr Pharm Des 10: 1727-1737.
27. Kuehn HS, Swindle EJ, Kim MS, Beaven MA, Metcalfe DD, et al. (2008) The phosphoinositide 3-kinase-dependent activation of Btk is required for optimal eicosanoid production and generation of reactive oxygen species in antigen-stimulated mast cells. J Immunol 181: 7706-7712.
28. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-1863.
29. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, et al. (2008) NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68: 8022-8030.
30. Baumann P, Mandl-Weber S, Oduncu F, Schmidmaier R, (2009) The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp Cell Res 315: 485-497.
31. Hauswirth AW, Natter S, Ghannadan M, Majlesi Y, Schernthaner GH, et al. (2002) Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. J Allergy Clin Immunol 110: 102-109.
32. Valent P, Ghannadan M, Akin C, Krauth MT, Selzer E, et al. (2004) On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts. Eur J Clin Invest 34: 41-52.
33. Shelburne CP, McCoy ME, Piekorz R, Sexl VV, Gillespie SR, et al. (2002) Stat5: an essential regulator of mast cell biology. Mol Immunol 38: 1187-1191.
34. Shelburne CP, McCoy ME, Piekorz R, Sexl V, Roh KH, et al. (2003) Stat5 expression is critical for mast cell development and survival. Blood 102: 1290-1297.
35. Baumgartner C, Cerny-Reiterer S, Sonneck K, Mayerhofer M, Gleixner KV, et al. (2009) Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. Am J Pathol 175: 2416-2429.
36. Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, et al. (2006) PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 107: 752-759.
37. Akin C, Brockow K, D'Ambrosio C, Kirshenbaum AS, Ma Y, et al. (2003) Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 31: 686-692.
38. Gabillot-Carré M, Lepelletier Y, Humbert M, de Sepuvelda P, Hamouda NP, et al. (2006) Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. Blood 108: 1065-1072.
39. Kim MS, Kuehn HS, Metcalfe DD, Gilfillan AM, (2008) Activation and function of the mTORC1 pathway in mast cells. J Immunol 180: 4586-4595.
40. Hauswirth AW, Escribano L, Prados A, Nuñez R, Mirkina I, et al. (2008) CD203c is overexpressed on neoplastic mast cells in systemic mastocytosis and is upregulated upon IgE receptor cross-linking. Int J Immunopathol Pharmacol 21: 797-806.
41. Valent P, Besemer J, Muhm M, Majdic O, Lechner K, et al. (1989) Interleukin 3 activates human blood basophils via high-affinity binding sites. Proc Natl Acad Sci USA 86: 5542-5546.
42. Mirkina I, Schweighoffer T, Kricek F, (2007) Inhibition of human cord blood-derived mast cell responses by anti-Fc epsilon RI mAb 15/1 versus anti-IgE Omalizumab. Immuno Lett 109: 120-128.
43. Butterfield JH, Weiler D, Dewald G, Gleich GJ, (1988) Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 12: 345-355.
44. Valent P, Ashman LK, Hinterberger W, Eckersberger F, Majdic O, et al. (1989) Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood 73: 1778-1785.
45. Hadzijusufovic E, Peter B, Gleixner KV, Schuch K, Pickl WF, et al. (2010) H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells. Exp Hematol 38: 896-907.
46. Valent P, Schmidt G, Besemer J, Mayer P, Zenke G, et al. (1989) Interleukin-3 is a differentiation factor for human basophils. Blood 73: 1763-1769.
47. Valent P, Spanblöchl E, Sperr WR, Sillaber C, Zsebo KM, et al. (1992) Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood 80: 2237-2245.
48. Krauth MT, Mirkina I, Herrmann H, Baumgartner C, Kneidinger M, et al. (2009) Midostaurin (PKC412) inhibits IgE-dependent activation and mediator release in human blood basophils and mast cells. Clin Exp Allerg 39: 1711-1720.
49. Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, et al. (2008) The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood 111: 3097-3107.
50. Breiteneder H, Pettenburger K, Bito A, Valenta R, Kraft D, et al. (1989) The gene coding for the major birch pollen allergen Betv1, is highly homologous to a pea disease resistance response gene. EMBO J 8: 1935-1938.
51. Füreder W, Agis H, Willheim M, Bankl HC, Maier U, et al. (1995) Differential expression of complement receptors on human basophils and mast cells. Evidence for mast cell heterogeneity and CD88/C5aR expression on skin mast cells. J Immunol 155: 3152-3160.